
Keywords: B2M; beta 2 microglobulin; CAR; cyclophophamide, alvocidib, rituximab; CDK; cyclin-dependent kinase; CLL; chronic lymphocytic leukemia; CR; complete response; CRS; cytokine release syndrome; DLT; dose limiting toxicity; ECOG; Eastern Cooperative Oncology